You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies

    SBC: CORNERSTONE RESEARCH GROUP INC            Topic: 101

    Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Zika viral pseudoinfectious virus as Zika vaccine candidate

    SBC: Tengen Biomedical Co            Topic: NIAID

    Executive Summary of Predicate SBIR/STTR Phase I Grant and Team TenGen Biomedical Co. and Howard University received an STTR Phase I grant (5R41AI129119-02) from the National Institute of Allergy and Infectious Diseases (NIAID) in 2017. The overall objective of our predicate STTR Phase I grant is to develop a safe, effective, and affordable Zika vaccine based on the novel concept of the third gene ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Immunotherapeutics to prevent HCV reinfection

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: r

    Project Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax spores are readily found in nature or produced in the laboratoryare resistant to harsh conditionsand can survive for a long time in the environmentThe microscopic spores could be formulated in powder ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Humanized Monoclonal Antibodies to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government